Medication info
Ezetimibe 10 mg (Ezetimibe) Tablet

Ezetimibe 10 mg (Ezetimibe) Tablet

Prescription medicationTablet
Ingredient · strength
Ezetimibe›10mg / 1 tablet
Manufacturer / importer
Hanmi Pharmaceutical Co., Ltd.
Appearance
White to almost white oval-shaped tablets
Packaging
30 tablets (10 tablets/PTPX3)/carton
Approval status
Active

MFDS item code 201600217 · Approved 2016.01.12 · Insurance code 643507500

Summary

Main use
Improvement of hypercholesterolemia, mixed dyslipidemia, and homozygous sitosterolemia
Who uses it
Adults
Adult dosage
A standard cholesterol-lowering diet should be continued during treatment with this medicine. The recommended dose of this medicine is 10 mg once daily, with or without food. When administered in combination with an HMG-CoA reductase inhibitor (in patients with primary hypercholesterolemia), start combination therapy with this medicine at the recommended initial dose of the HMG-CoA reductase inhibitor. If the patient is already receiving a high dose of an HMG-CoA reductase inhibitor, administer this medicine concomitantly while maintaining the HMG-CoA reductase inhibitor dose. When administered in combination with fenofibrate (in patients with mixed hyperlipidemia), administer this medicine with fenofibrate 160mg once daily or 200mg once daily (see Precautions for Use, 4. General Precautions). 1. Administration to patients with hepatic impairment No dose adjustment is required in patients with mild hepatic impairment; however, this medicine is not recommended in patients with moderate to severe hepatic impairment (see Precautions for Use, 2. Patients Requiring Caution). 2. Administration to patients with renal impairment No dose adjustment is required in patients with renal impairment. 3. Administration to older adults No dose adjustment is required when administering to older adults. 4. Concomitant administration with bile acid sequestrants Administer this medicine at least 2 hours before or 4 hours after administration of a bile acid sequestrant (see Precautions for Use, 5. Drug Interactions).

Ingredients

Manufacturer
Hanmi Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of hypercholesterolemia, mixed dyslipidemia, and homozygous sitosterolemia

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • non-familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • homozygous familial sitosterolemia
  • homozygous sitosterolemia
  • hypercholesterolemia
  • dyslipidemia
View approved original text

This medication helps lower elevated total cholesterol, low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B levels in patients with primary hypercholesterolemia. It is especially used in patients with heterozygous familial and non-familial hypercholesterolemia in conjunction with dietary measures, either alone or in combination with HMG-CoA reductase inhibitors. In patients with mixed dyslipidemia, it is used alongside dietary measures and fenofibrate to reduce total cholesterol, LDL-C, apolipoprotein B, and non-high-density lipoprotein cholesterol (non-HDL-C). Additionally, in patients with homozygous familial hypercholesterolemia, it is used as an adjunct to other lipid-lowering therapies or given together with statins to enhance therapeutic effect. In patients with homozygous sitosterolemia, it helps lower elevated sitosterol and campesterol levels and is used in conjunction with appropriate dietary measures. This drug is quite effective in lowering the risk of dyslipidemia and related vascular diseases and is used to improve patients' cholesterol levels alongside dietary measures.

Dosage and Administration

Adult dosage

A standard cholesterol-lowering diet should be continued during treatment with this medicine. The recommended dose of this medicine is 10 mg once daily, with or without food. When administered in combination with an HMG-CoA reductase inhibitor (in patients with primary hypercholesterolemia), start combination therapy with this medicine at the recommended initial dose of the HMG-CoA reductase inhibitor. If the patient is already receiving a high dose of an HMG-CoA reductase inhibitor, administer this medicine concomitantly while maintaining the HMG-CoA reductase inhibitor dose. When administered in combination with fenofibrate (in patients with mixed hyperlipidemia), administer this medicine with fenofibrate 160mg once daily or 200mg once daily (see Precautions for Use, 4. General Precautions). 1. Administration to patients with hepatic impairment No dose adjustment is required in patients with mild hepatic impairment; however, this medicine is not recommended in patients with moderate to severe hepatic impairment (see Precautions for Use, 2. Patients Requiring Caution). 2. Administration to patients with renal impairment No dose adjustment is required in patients with renal impairment. 3. Administration to older adults No dose adjustment is required when administering to older adults. 4. Concomitant administration with bile acid sequestrants Administer this medicine at least 2 hours before or 4 hours after administration of a bile acid sequestrant (see Precautions for Use, 5. Drug Interactions).

Precautions

This medication should not be used in patients who are allergic to specific components. Patients with liver dysfunction or abnormally high liver enzyme levels should avoid the concomitant use of this medication with specific lipid-lowering agents. Pregnant or nursing women are advised against taking this drug or specific lipid-lowering agents, and they must consult with a physician. The use of this drug is not recommended in patients with moderate to severe liver impairment. While this drug is generally safe, side effects such as headaches, abdominal pain, diarrhea, fatigue, muscle pain, etc., may occur, and if any peculiar symptoms arise, consultation with healthcare personnel should be sought. If symptoms like muscle pain or weakness occur, notify a doctor immediately and get necessary tests. Patients with impaired kidney function can use this drug without special dose adjustment, but careful monitoring by healthcare personnel is necessary. Drug interactions may occur when used in combination with other drugs, so patients should inform their healthcare provider about any medications they are taking. Particularly, caution is required when taken with anticoagulants, immunosuppressants, or lipid-lowering agents. The safety of this drug during pregnancy has not been established, so consult a physician if planning to become pregnant or if pregnant. Nursing women should avoid using this medication as it may be excreted in breast milk. It is not recommended for children under 6 years of age, and dosing in children or adolescents should be followed as directed by healthcare personnel. Elderly patients can generally use it safely, but responses may differ based on individual health status, so caution is needed. In case of overdose, there is no specific antidote, and appropriate treatment should be administered based on symptoms; it should be kept out of reach of children.

Side effects

  • Fatigue
  • abdominal pain
  • diarrhea
  • viral infection
  • pharyngitis
  • sinusitis
  • arthralgia
  • low back pain
  • cough
  • chest pain
Show 61 more
  • dizziness
  • headache
  • constipation
  • bloating
  • nausea
  • increased AST
  • increased ALT
  • myalgia
  • myopathy
  • rhabdomyolysis
  • hepatitis
  • thrombocytopenia
  • pancreatitis
  • sensory disturbances
  • depression
  • cholelithiasis
  • cholecystitis
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • eosinophilia
  • drug reaction with systemic symptoms
  • erythema multiforme
  • drug-induced liver injury
  • chest discomfort
  • chest unease
  • edema
  • asthenia
  • generalized edema
  • headache
  • diabetic neuropathy
  • tremor
  • epigastric pain
  • vomiting
  • gastritis
  • xerostomia
  • discomfort in the epigastrium
  • belching
  • gastrointestinal disturbances
  • gastroesophageal reflux disease
  • tongue disorders
  • palpitations
  • congestive heart failure
  • myocardial ischemia
  • flushing
  • sputum
  • rhinorrhea
  • limb pain
  • anemia
  • splenomegaly
  • urticaria
  • hyperhidrosis
  • rash
  • pruritus
  • upper respiratory infection
  • conjunctival hyperemia
  • renal failure
  • abnormal liver function
  • increased serum creatinine
  • elevated blood pressure
  • increased blood urea
  • increased serum creatine phosphokinase

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. It is important to maintain storage temperatures between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

White to almost white oval-shaped tablets

Package unit

30 tablets (10 tablets/PTPX3)/carton

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.